TW202019455A - Composition for tonifying kidney and strengthening Yang and preparation method and use thereof - Google Patents
Composition for tonifying kidney and strengthening Yang and preparation method and use thereof Download PDFInfo
- Publication number
- TW202019455A TW202019455A TW108102289A TW108102289A TW202019455A TW 202019455 A TW202019455 A TW 202019455A TW 108102289 A TW108102289 A TW 108102289A TW 108102289 A TW108102289 A TW 108102289A TW 202019455 A TW202019455 A TW 202019455A
- Authority
- TW
- Taiwan
- Prior art keywords
- servings
- composition
- astragalus
- patent application
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 210000003734 kidney Anatomy 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 5
- 238000005728 strengthening Methods 0.000 title abstract description 6
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 39
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 35
- 241000208340 Araliaceae Species 0.000 claims abstract description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 25
- 235000008434 ginseng Nutrition 0.000 claims abstract description 25
- 206010010774 Constipation Diseases 0.000 claims abstract description 20
- 241000005787 Cistanche Species 0.000 claims abstract description 16
- 241001061264 Astragalus Species 0.000 claims description 33
- 235000006533 astragalus Nutrition 0.000 claims description 33
- 210000004233 talus Anatomy 0.000 claims description 33
- 230000002509 aphrodisiac effect Effects 0.000 claims description 32
- 239000003048 aphrodisiac agent Substances 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 19
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 16
- 229940010454 licorice Drugs 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 15
- 244000241838 Lycium barbarum Species 0.000 claims description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 14
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 13
- 235000017803 cinnamon Nutrition 0.000 claims description 13
- 235000015468 Lycium chinense Nutrition 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 12
- 235000004879 dioscorea Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 241000336291 Cistanche deserticola Species 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 8
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 244000197580 Poria cocos Species 0.000 claims description 7
- 235000008599 Poria cocos Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229920002379 silicone rubber Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 230000036039 immunity Effects 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000009636 Huang Qi Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 description 17
- 240000004670 Glycyrrhiza echinata Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 244000281702 Dioscorea villosa Species 0.000 description 10
- 235000002723 Dioscorea alata Nutrition 0.000 description 9
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 9
- 239000008141 laxative Substances 0.000 description 8
- 230000002475 laxative effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- -1 kidney Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 206010065360 Anal prolapse Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000002915 Solanum macrocarpon Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本發明涉及功能食品領域,具體涉及一種補腎壯陽的組合物。The present invention relates to the field of functional foods, and in particular to a kidney and aphrodisiac composition.
隨著人們物質文化生活水平的提高,越來越多的人開始注重養生,保健和美容等,而且他們已認識到化學性藥物的嚴重副作用,開始向傳統的中藥回歸,尤其是男性健康水平逐年呈下降趨勢,並出現腎虛、氣血不足、抵抗力下降等,從而導致不少疾病的產生,如體虛脫發、頭暈目眩、腰酸背痛、失眠煩熱等病症,以及陽萎早洩、前列腺疾病等性機能衰退。西醫界常使用糖皮質激素治療腎臟疾病,在一定程度上緩解了病人的痛苦,提高了短期內的療效。但是毫無控制的激素應用,使患者出現了各種不可逆轉的嚴重症狀。With the improvement of people's material and cultural living standards, more and more people begin to pay attention to health, health care and beauty, etc., and they have recognized the serious side effects of chemical drugs and began to return to traditional Chinese medicine, especially the health level of men year by year There is a downward trend, and there are kidney deficiency, deficiency of qi and blood, decreased resistance, etc., which leads to many diseases, such as hair loss, dizziness, back pain, insomnia, and fever, as well as impotence, premature ejaculation, and prostate disease. Equal sex function declines. Western medicine circles often use glucocorticoids to treat kidney diseases, which relieves the patients' pain to a certain extent and improves the short-term efficacy. However, the uncontrolled use of hormones has caused patients to experience various irreversible serious symptoms.
隨著人們飲食結構的改變及精神心理和社會因素的影響,便秘發病率有增高趨勢。便秘在人群中的患病率高達27%,可以影響各年齡層的人。由於便秘是一種較為普遍的症狀,症狀輕重不一,大部分人常常不去特殊理會,認為便秘不是病,不用治療,但實際上便秘的危害很大。便秘在有些疾病如結腸癌、肝性腦病、乳腺疾病、早老性癡呆的發生中產生重要作用,這方面有很多研究報告;便秘在急性心肌梗死、腦血管意外病人可導致生命意外,有很多慘痛事例讓我們警覺;部分便秘和肛腸疾病,如痔、肛裂等有密切的關係。With the change of people's diet structure and the influence of mental, psychological and social factors, the incidence of constipation tends to increase. The prevalence of constipation in the population is as high as 27%, which can affect people of all ages. Because constipation is a more common symptom, the symptoms vary, and most people often do not pay special attention to it, thinking that constipation is not a disease and does not need treatment, but in fact constipation is very harmful. Constipation plays an important role in the occurrence of certain diseases such as colon cancer, hepatic encephalopathy, breast disease, and Alzheimer's disease. There are many research reports in this regard; constipation can cause life accidents in patients with acute myocardial infarction and cerebrovascular accidents, and there are many pains Cases alert us; some constipation is closely related to anorectal diseases such as hemorrhoids and anal fissures.
青少年皮膚應是白皙細膩,紅潤光澤,富有彈性,隨著年齡增長,皮膚開始自然衰老,加之精神、營養、內分泌、藥物及紫外線照射等作用,可加速皮膚老化,表現為面色萎黃粗糙,彈性減退,皮膚萎縮,皺紋顯現及色素沉著。皮膚衰老原因很多,但其主要原因是與自由基對皮膚損害有著密切關係。前述皮膚老化因素可在體內產生大量自由基,藉由過氧化作用,最後造成細胞組織功能及細胞形態結構損害,表現為皮膚變性、萎縮、粗糙無光、彈性減退出現皺紋等。The skin of young people should be fair and delicate, with rosy luster and full of elasticity. With age, the skin begins to age naturally. Together with the effects of spirit, nutrition, endocrine, drugs and ultraviolet radiation, it can accelerate the aging of the skin. It fades, the skin shrinks, the appearance of wrinkles and hyperpigmentation. There are many reasons for skin aging, but the main reason is that it is closely related to free radical damage to the skin. The aforementioned skin aging factors can generate a large amount of free radicals in the body, and through peroxidation, finally cause damage to cell tissue function and cell morphology and structure, manifested as skin degeneration, atrophy, roughness and dullness, and wrinkles and so on.
目前,亟待開發一種全面、有效地提高免疫力、壯陽補腎、潤腸通便、延緩衰老且安全的功能食品。At present, there is an urgent need to develop a functional food that comprehensively and effectively improves immunity, nourishes the kidneys, relaxes the bowels, delays aging, and is safe.
本發明的目的是克服習知技術的缺陷,提供一種具有補腎壯陽作用的組合物。本發明提供的組合物將人參、黃芪、椰子瓤、肉蓯蓉等組分進行配伍聯合使用,可以達到協同增效的作用,可以有效的提高免疫力、壯陽補腎、潤腸通便、延緩衰老。The purpose of the present invention is to overcome the shortcomings of the conventional technology, and to provide a composition with a kidney and aphrodisiac effect. The composition provided by the invention combines and uses the components of ginseng, astragalus, coconut flesh, and cistanche, and can achieve the synergistic effect, and can effectively improve the immunity, aphrodisiac, kidney, laxative and laxative.
具體而言,本發明提供的補腎壯陽的組合物採用包括如下組分的原料製備而成:人參,黃芪,椰子瓤以及肉蓯蓉。Specifically, the kidney and aphrodisiac composition provided by the present invention is prepared using raw materials including the following components: ginseng, astragalus, coconut flesh and cistanche.
本發明採用的人參為五加科植物人參的乾燥根。人參的主要成分是人參皂苷,具有清除體內過氧化的自由基、抗衰老、抗疲勞、增強記憶力、提高免疫力、保護神經系統、保護心肌系統、抗腫瘤細胞的擴散和轉移、加速腫瘤細胞的衰亡等作用。The ginseng used in the present invention is the dried root of the ginseng of Araliaceae. The main component of ginseng is ginsenoside, which has the functions of eliminating free radicals in the body, anti-aging, anti-fatigue, enhancing memory, improving immunity, protecting the nervous system, protecting the myocardial system, anti-tumor cell proliferation and metastasis, and accelerating the growth of tumor cells. Decline and other effects.
本發明採用的黃芪為豆科植物蒙古黃芪的根。黃芪具有補氣固表、托毒排膿、利尿、生肌的作用,用於氣虛乏力、久瀉脫肛、自汗、水腫、子官脫垂、慢性腎炎蛋白尿、糖尿病、瘡口久不癒合。The astragalus used in the present invention is the root of the leguminous plant Mongolian astragalus. Astragalus has the effects of invigorating qi and solidifying the surface, supporting poison and purging, diuresis, and muscular growth. It is used for qi deficiency and fatigue, prolapsed anal prolapse, spontaneous sweating, edema, prolapse of the child's official body, proteinuria in chronic nephritis, diabetes, and sores.
本發明採用的椰子瓤為棕櫚科植物椰子的胚乳。椰子瓤有殺絛蟲作用,飲其汁而食其肉可驅蟲,治於益氣,去風。The coconut crumb used in the present invention is the endosperm of the palm family coconut. Coconut flesh has the effect of killing tapeworms. Drinking its juice and eating its flesh can repel insects.
本發明採用的肉蓯蓉為列當科植物肉蓯蓉或蓯蓉、迷肉蓯蓉等的肉質莖。肉蓯蓉具有補腎、益精、潤燥、滑腸的功效,可治療男子陽痿,女子不孕,帶下,血崩,腰膝冷痛,血枯便秘。The Cistanche deserticola used in the present invention is Cistanche deserticola, Cistanche deserticola, Cistanche deserticola and other fleshy stems. Cistanche has the effects of nourishing the kidney, improving essence, moisturizing, and smoothing the intestines. It can treat impotence in men, infertility in women, bring down, blood collapse, cold pain in the waist and knees, and constipation in blood dryness.
本發明所選用的原料均為對人體安全,對環境友好;本發明進步性地發現,將這幾種成分進行配伍聯合使用,可以達到協同增效的作用,可以有效的提高免疫力、壯陽補腎、潤腸通便、延緩衰老。更重要的是,人參、黃芪、肉蓯蓉雖然是中藥方劑中經典的搭配方式,但其存在的缺陷是容易引發上火,並且對於體質虛弱的人,過於大補的組方會出現“虛不受補”的情況,而導致不能產生良好的療效。本發明意外地發現引入椰子瓤這一組分可以改善以上缺陷。一方面,椰子生於長熱帶地區海岸,為陽中之物,取其陰中求陽之意;另一方面,椰子瓤入肺、脾經,取其益氣健脾之功效,調和組方中滋膩的補藥藥性,緩解補藥形成中滿的症狀,改善補藥虛不受補的缺陷。整體組方從潤腸通便、增強免疫力等多角度調節身體整體機能,繼而實現補腎壯陽的效果。本發明藉由大量實踐發現,當其中黃芪與椰子瓤的重量比在1:0.1~1:10的範圍內時,各組分之間可以發揮最佳的協同增效的作用。The raw materials selected in the present invention are all safe to the human body and friendly to the environment; the present invention progressively finds that the combined use of these ingredients can achieve a synergistic effect, which can effectively improve immunity, aphrodisiac and kidney , Laxative and laxative, delay aging. More importantly, although ginseng, astragalus, and cistanche are the classic matching methods in traditional Chinese medicine prescriptions, their shortcomings are easy to cause irritation, and for those with weak constitutions, the overdose formula will appear The situation of "compensating" cannot lead to good curative effect. The present invention has unexpectedly found that the introduction of the component of coconut flesh can improve the above defects. On the one hand, coconuts were born on the coast of the long tropical area, and they are the things in the sun, and take the meaning of seeking yin in the yin; on the other hand, the coconuts are stuffed into the lungs and spleen channels to take the effect of nourishing qi and strengthening the spleen, reconciling the greasiness in the formula. The tonicity of the tonic, alleviates the symptoms of tonic formation in the tonic, and improves the deficiency of tonic and not tonic. The overall formula regulates the overall function of the body from various angles such as laxative and laxative, and enhances immunity, and then achieves the effect of kidney and aphrodisiac. The present invention has found through a lot of practice that when the weight ratio of astragalus and coconut flakes is in the range of 1:0.1~1:10, each component can play the best synergistic effect.
作為本發明的一種較佳方案,所述組合物以重量份計,採用包括如下組分的原料製備而成: 人參1~10份; 黃芪2~30份; 椰子瓤0.5~30份;以及 肉蓯蓉1~15份; 其中,黃芪與椰子瓤的重量比在1:0.1~1:10的範圍內。As a preferred solution of the present invention, the composition is prepared by using raw materials including the following components in parts by weight: 1~10 servings of ginseng; 2-30 copies of astragalus; Coconut flakes 0.5~30 servings; and 1-15 Cistanche deserticola; Among them, the weight ratio of astragalus and coconut flesh is in the range of 1:0.1~1:10.
本發明提供的組合物可以僅由人參、黃芪、椰子瓤以及肉蓯蓉為原料製備而成;此時,為了提高四種組分之間的協同作用,其中本發明進一步較佳為黃芪與椰子瓤的重量比在1:5~1:10的範圍內。The composition provided by the present invention can be prepared by using only ginseng, astragalus, coconut flesh and cistanche as raw materials; at this time, in order to improve the synergy between the four components, the present invention is more preferably that of astragalus and coconut flesh The weight ratio is in the range of 1:5~1:10.
本發明提供的組合物還可以採用其它原料輔佐人參、黃芪、椰子瓤以及肉蓯蓉發揮功效,進一步實現協同作用,從而多角度調節身體整體機能,繼而實現補腎壯陽的效果。所述其它原料可選用山藥、枸杞、茯苓、肉桂、甘草中的一種或多種。在加入上述其它原料之後,為了提高各組分之間的協同作用,其中本發明進一步較佳為黃芪與椰子瓤的重量比在1:0.1~1:1的範圍內,更佳在1:0.1~1:0.5的範圍內。The composition provided by the present invention can also use other raw materials to assist ginseng, astragalus, coconut flesh and cistanche to exert the effect, and further achieve synergy, thereby adjusting the overall function of the body from multiple angles, and then achieving the effect of kidney and aphrodisiac. The other raw materials may be one or more of yam, wolfberry, poria, cinnamon, and licorice. After adding the above other raw materials, in order to improve the synergy between the components, the present invention further preferably has a weight ratio of astragalus and coconut flakes in the range of 1:0.1~1:1, more preferably 1:0.1 ~1: Within the range of 0.5.
本發明採用的山藥為薯蕷科植物薯蕷的乾燥根莖。味甘,性平。歸脾、肺、腎經,能調節免疫力、抗氧化、抗衰老、抗腫瘤,具有明顯降血糖作用。本發明較佳所述組合物中山藥的用量為2~10份。The yam used in the present invention is the dried rhizome of the Dioscorea plant. Sweet and flat. Returning to the spleen, lung and kidney channels, it can regulate immunity, anti-oxidation, anti-aging, anti-tumor, and has a significant effect of lowering blood sugar. The preferred amount of yam in the composition of the present invention is 2-10 parts.
本發明採用的枸杞為茄科植物寧夏枸杞的乾燥成熟果實,味甘,性平,歸肝、腎經。枸杞具有增強免疫力、抗氧化、降血脂、降血糖、保護肝臟和延緩衰老的作用。本發明較佳所述組合物中枸杞的用量為2~10份。The wolfberry used in the present invention is the dried and ripe fruit of the nightshade plant Ningxia wolfberry. Wolfberry has the effects of enhancing immunity, anti-oxidation, lowering blood fat, lowering blood sugar, protecting the liver and delaying aging. Preferably, the amount of wolfberry in the composition of the present invention is 2-10 parts.
本發明採用的茯苓為多孔菌科真菌茯苓的乾燥菌核,味甘、淡,性平,歸心、肺、脾、腎經,有利水滲濕,健脾,寧心之功效。茯苓具有增強免疫力、抗腫瘤、抗衰老、降血脂、保肝、利尿、抗炎、助眠等作用。本發明較佳所述組合物中茯苓的用量為1~10份。The Poria cocos used in the present invention is the dried sclerotia of Poria coccinea fungus Poria cocos, sweet, light, and calm, to the heart, lungs, spleen, and kidney meridian, which is beneficial to water infiltration, strengthening the spleen, and calming the heart. Poria has the functions of strengthening immunity, anti-tumor, anti-aging, lowering blood fat, protecting liver, diuretic, anti-inflammatory, and sleep aid. The preferred amount of Poria in the composition of the present invention is 1-10 parts.
本發明採用的肉桂為樟科植物肉桂的乾燥樹皮,味辛、甘,性大熱,歸腎、脾、心、肝經。肉桂在臨床上可鎮痛解痙,具有解熱、降血糖和血壓、抗菌、抗腫瘤、抗潰瘍和壯陽等作用。本發明較佳所述組合物中肉桂的用量為0.5~5份。The cinnamon used in the present invention is the dried bark of Cinnamomum camphora, which has a spicy, sweet, and hot sex, and belongs to the kidney, spleen, heart, and liver meridian. Cinnamon is clinically analgesic and antispasmodic, with antipyretic, hypoglycemic and blood pressure, antibacterial, antitumor, antiulcer and aphrodisiac effects. The preferred amount of cinnamon in the composition of the present invention is 0.5-5 parts.
本發明採用的甘草為豆科植物甘草、脹果甘草或光果甘草的乾燥根和根莖,味甘,性平,有歸心、肺、脾、胃經。甘草具有抗衰老、抗炎、抗病毒、降壓、增強機體免疫力、提高生理機能、抑制癌細胞生長等作用。本發明較佳所述組合物中甘草的用量為1~10份。The licorice used in the present invention is the dried roots and rhizomes of legume licorice, licorice bulge or licorice glabra, which has a sweet taste and a calm nature, and has heart, lung, spleen and stomach meridian. Licorice has anti-aging, anti-inflammatory, anti-viral, antihypertensive, enhancing body immunity, improving physiological functions, and inhibiting the growth of cancer cells. The preferred amount of licorice in the composition of the present invention is 1-10 parts.
本發明較佳選用上述五種原料共同與人參、黃芪、椰子瓤以及肉蓯蓉使用。In the present invention, the above five kinds of raw materials are preferably used together with ginseng, astragalus, coconut flesh and cistanche.
作為本發明的一種較佳方案,所述組合物以重量份計,採用包括如下組分的原料製備而成: 人參2~7份; 黃芪6~12份; 椰子瓤1~9份; 肉蓯蓉4~11份; 山藥2~10份; 枸杞2~10份; 茯苓1~10份; 肉桂0.5~5份;以及 甘草1~10份; 其中,黃芪與椰子瓤的重量比在1:0.1~1:10的範圍內,較佳在1:0.1~1:1的範圍內。As a preferred solution of the present invention, the composition is prepared by using raw materials including the following components in parts by weight: 2~7 servings of ginseng; 6~12 servings of astragalus; Coconut flakes 1~9 servings; 4 to 11 servings of Cistanche deserticola; 2~10 servings of yam; 2-10 goji berries; Poria 1~10 servings; 0.5 to 5 servings of cinnamon; and 1~10 servings of licorice; Among them, the weight ratio of astragalus and coconut flesh is in the range of 1:0.1~1:10, preferably in the range of 1:0.1~1:1.
作為本發明的一種較佳方案,所述組合物採用包括如下重量份的原料製備而成: 人參2~3份; 黃芪9~11份; 椰子瓤1~2份; 肉蓯蓉9~11份; 山藥5~7份; 枸杞5~7份; 茯苓5~7份; 肉桂0.5~1.5份;以及 甘草2~4份; 其中,所述黃芪與椰子瓤的重量比在1:0.1~1:0.5的範圍內。As a preferred solution of the present invention, the composition is prepared by using raw materials including the following parts by weight: 2~3 servings of ginseng; 9 to 11 servings of astragalus; Coconut flakes 1-2 servings; 9 to 11 servings of Cistanche; 5~7 servings of yam; 5~7 servings of wolfberry; Poria cocos 5~7 servings; 0.5 to 1.5 servings of cinnamon; and 2~4 servings of licorice; Wherein, the weight ratio of astragalus to coconut flesh is in the range of 1:0.1~1:0.5.
本發明提供的組合物可按照本領域常規的方法製備而成。為了進一步提高上述組合物的補腎壯陽效果,且便於作為有效成分與輔料混合製備產品,本發明較佳所述組合物採用如下方法製備而成:取各原料,混合後用水充分浸泡後文火煎煮,再超音波萃取,分離上清液,濃縮,乾燥,即得。本發明藉由大量實踐發現,將原料先文火煎煮、再超音波萃取,所得的萃取物可以將各原料中的有效成分最大限度的富集,從而確保有效成分之間能夠發揮協同作用。The composition provided by the present invention can be prepared according to conventional methods in the art. In order to further improve the kidney and aphrodisiac effect of the above composition, and to facilitate the preparation of products by mixing as an active ingredient and auxiliary materials, the composition of the present invention is preferably prepared by the following method: take each raw material, mix it with water, soak it thoroughly, and then cook it with a fire. , Ultrasonic extraction, the supernatant is separated, concentrated and dried, that is. The present invention has found through a lot of practice that the raw materials are decocted and ultrasonically extracted, and the resulting extract can enrich the effective ingredients in each raw material to the greatest extent, thereby ensuring that the effective ingredients can play a synergistic role.
本發明同時保護所述組合物在製備補腎壯陽的食品或保健品中的應用。The invention also protects the application of the composition in the preparation of foods or health products for kidney and aphrodisiac.
具體而言,本發明提供的補腎壯陽的食品或保健品,是以所述組合物為有效成分,加入食品或保健品的常規輔料,按照本領域的常規方法製備而成。Specifically, the food or health care product for kidney and aphrodisiac provided by the present invention is prepared by using the composition as an effective ingredient and adding conventional auxiliary materials of food or health care products according to a conventional method in the art.
本發明同時保護所述組合物在製備預防或治療便秘的藥物中的應用。The invention also protects the application of the composition in the preparation of a medicine for preventing or treating constipation.
作為一種具體應用方式,用於預防或治療便秘的藥物以所述組合物為有效成分,加入藥物的常規輔料,按照本領域的常規方法製備而成。所述藥物較佳為口服劑型,如常見的片劑、膠囊劑、口服液等等。為了便於患者服用,並且以最佳的藥代動力學方式發揮潤腸通便的作用,本發明較佳所述藥物為片劑。As a specific application mode, the medicine for preventing or treating constipation uses the composition as an active ingredient, and is added with conventional auxiliary materials of the medicine, and is prepared according to a conventional method in the art. The medicine is preferably an oral dosage form, such as common tablets, capsules, oral liquid, and the like. In order to facilitate the patient to take, and to play the role of laxative in the best pharmacokinetics, the present invention preferably said tablets are tablets.
具體而言,本發明提供一種補腎壯陽的片劑,在本發明提供的組合物基礎上,還包括黏合劑、崩解劑、潤滑劑、矯味劑以及填充劑。Specifically, the present invention provides a tablet for kidney and aphrodisiac, and on the basis of the composition provided by the present invention, further includes a binder, a disintegrant, a lubricant, a flavoring agent, and a filler.
其中:among them:
所述的黏合劑可選自澱粉漿、明膠溶液、羥甲基纖維素鈉、羥丙基纖維素中的一種或幾種。在所述片劑的原料中,所述黏合劑的用量較佳為0.01~8份,更佳為0.1~0.5份。The binder may be selected from one or more of starch slurry, gelatin solution, sodium hydroxymethyl cellulose, and hydroxypropyl cellulose. In the raw material of the tablet, the amount of the binder is preferably 0.01 to 8 parts, more preferably 0.1 to 0.5 parts.
所述崩解劑可選自乾澱粉、羥甲基澱粉鈉、低取代羥丙基纖維素鈉、交聯羥甲基纖維素鈉中的一種或幾種。在所述片劑的原料中,所述崩解劑的用量較佳為0.01~3份,更佳為0.5~1份。The disintegrant may be selected from one or more of dry starch, sodium hydroxymethyl starch, low-substituted hydroxypropyl cellulose sodium, and cross-linked hydroxymethyl cellulose sodium. In the raw material of the tablet, the amount of the disintegrant is preferably 0.01 to 3 parts, more preferably 0.5 to 1 part.
所述潤滑劑可選自硬脂酸鎂、滑石粉、微粉矽膠、氫化植物油、中的一種或幾種。在所述片劑的原料中,所述潤滑劑的用量較佳為0.01~1.5份,更佳為0.01~0.09份。The lubricant may be selected from one or more of magnesium stearate, talc powder, micropowder silicone rubber, hydrogenated vegetable oil, and the like. In the raw material of the tablet, the amount of the lubricant is preferably 0.01 to 1.5 parts, more preferably 0.01 to 0.09 parts.
所述矯味劑可選自糖精鈉、三氯蔗糖、甜蜜素、甜菊苷、阿斯巴甜或甜菊糖中的一種或幾種。在所述片劑的原料中,所述矯味劑的用量較佳為0.01~1.5份,更佳為0.1~0.5份。The flavoring agent may be selected from one or more of sodium saccharin, sucralose, cyclamate, stevioside, aspartame or stevioside. In the raw material of the tablet, the amount of the flavoring agent is preferably 0.01 to 1.5 parts, more preferably 0.1 to 0.5 parts.
所述填充劑可選自澱粉、糊精、甘露醇、赤蘚糖醇、微晶纖維素中的一種或幾種。在所述片劑的原料中,所述填充劑的用量較佳為0.5~10份,更佳為0.5~1份。The filler may be selected from one or more of starch, dextrin, mannitol, erythritol, and microcrystalline cellulose. In the raw material of the tablet, the amount of the filler is preferably 0.5 to 10 parts, more preferably 0.5 to 1 part.
作為本發明的一種具體實施方案,所述藥物以所述組合物為有效成分,還包括如下重量份的輔料: 羥甲基纖維素鈉0.01~8份; 乾澱粉0.01~3份; 硬脂酸鎂0.01~1.5份; 糖精鈉0.01~1.5份;以及 微晶纖維素0.5~10份。As a specific embodiment of the present invention, the medicine uses the composition as an active ingredient, and further includes the following parts by weight of auxiliary materials: 0.01-8 parts of hydroxymethyl cellulose sodium; 0.01~3 servings of dry starch; 0.01~1.5 servings of magnesium stearate; 0.01 to 1.5 servings of saccharin sodium; and 0.5 to 10 servings of microcrystalline cellulose.
作為本發明的一種具體實施方案,所述藥物以所述組合物為有效成分,還包括如下重量份的輔料: 羥甲基纖維素鈉0.1~0.5份; 乾澱粉0.5~1份; 硬脂酸鎂0.01~0.09份; 糖精鈉0.1~0.5份;以及 微晶纖維素0.5~1份。As a specific embodiment of the present invention, the medicine uses the composition as an active ingredient, and further includes the following parts by weight of auxiliary materials: 0.1~0.5 parts of sodium hydroxymethyl cellulose; 0.5~1 serving of dry starch; 0.01~0.09 parts of magnesium stearate; 0.1 to 0.5 servings of saccharin sodium; and 0.5 to 1 serving of microcrystalline cellulose.
本發明同時提供上述藥物的製備方法,具體包括如下步驟:將所述組合物先與填充劑、崩解劑以及矯味劑混合均勻,再加入黏合劑混合均勻,乾燥後整粒,再加入潤滑劑混合均勻,壓片製成片劑。The present invention also provides a method for preparing the above-mentioned medicine, which specifically includes the steps of: mixing the composition with a filler, a disintegrant, and a flavoring agent uniformly, then adding a binder to mix uniformly, drying, and granulating, and then adding a lubricant Mix well and press to make tablets.
本發明提供的組合物以人參、黃芪、椰子瓤以及肉蓯蓉等中藥作為原料,上述原料均為對人體安全,對環境友好;將這幾種成分進行配伍聯合使用,可以達到協同增效的作用,可以有效的提高免疫力、壯陽補腎、潤腸通便、延緩衰老。The composition provided by the present invention uses traditional Chinese medicines such as ginseng, astragalus, coconut flesh, and cistanche as the raw materials. The above raw materials are safe for the human body and environmentally friendly; combining and using these components together can achieve a synergistic effect. Can effectively improve immunity, aphrodisiac, kidney, laxative, and delay aging.
以下實施例用於說明本發明,但不用來限制本發明的範圍。The following examples are used to illustrate the present invention, but are not used to limit the scope of the present invention.
實施例1Example 1
本實施例提供了一種補腎壯陽的組合物,其採用如下原料製備而成:人參10kg,黃芪2kg,椰子瓤18kg,肉蓯蓉15kg。This example provides a kidney and aphrodisiac composition prepared from the following raw materials: ginseng 10kg, astragalus 2kg, coconut flesh 18kg, and Cistanche deserticola 15kg.
所述組合物採用如下方法製備而成:取各原料,混合後用水充分浸泡後文火煎煮,再超音波萃取30min,分離上清液,濃縮,噴霧乾燥,即得。The composition is prepared by the following method: each raw material is taken, mixed, fully immersed in water, simmered in water, and then subjected to ultrasonic extraction for 30 minutes, the supernatant is separated, concentrated, and spray-dried.
實施例2Example 2
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,各原料用量為:人參8kg,黃芪6kg,椰子瓤30kg,肉蓯蓉1kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that the amount of each raw material is: 8kg of ginseng, 6kg of astragalus, 30kg of coconut flesh, and 1kg of Cistanche deserticola.
實施例3Example 3
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,各原料用量為:人參1kg,黃芪30kg,椰子瓤0.5kg,肉蓯蓉13kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that the amount of each raw material is: 1kg of ginseng, 30kg of astragalus, 0.5kg of coconut flesh, and 13kg of Cistanche deserticola.
實施例4Example 4
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,其採用如下原料製備而成:人參7kg,黃芪6kg,椰子瓤3kg,肉蓯蓉4kg,山藥10kg,枸杞2kg,茯苓1kg,肉桂2kg,甘草10kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that it is prepared using the following raw materials: ginseng 7kg, astragalus 6kg, coconut flesh 3kg, cistanche 4kg, yam 10kg, wolfberry 2kg, Poria cocos 1kg, cinnamon 2kg, licorice 10kg.
實施例5Example 5
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,其採用如下原料製備而成:人參3kg,黃芪12kg,椰子瓤9kg,肉蓯蓉11kg,山藥3kg,枸杞3kg,茯苓2kg,肉桂0.5kg,甘草2kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that it is prepared from the following raw materials: ginseng 3kg, astragalus 12kg, coconut flesh 9kg, cistanche 11kg, yam 3kg, wolfberry 3kg, Poria 2kg, cinnamon 0.5kg, licorice 2kg.
實施例6Example 6
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,其採用如下原料製備而成:人參3kg,黃芪7kg,椰子瓤2kg,肉蓯蓉5kg,山藥2kg,枸杞10kg,茯苓10kg,肉桂5kg,甘草1kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that it is prepared from the following raw materials: ginseng 3kg, astragalus 7kg, coconut flesh 2kg, cistanche 5kg, yam 2kg, wolfberry 10kg, Poria cocos 10kg, cinnamon 5kg, licorice 1kg.
實施例7Example 7
本實施例提供了一種補腎壯陽的組合物,與實施例1相比,區別僅在於,其採用如下原料製備而成:人參2kg,黃芪10kg,椰子瓤1kg,肉蓯蓉10kg,山藥6kg,枸杞6kg,茯苓6kg,肉桂1kg,甘草3kg。This example provides a kidney and aphrodisiac composition. Compared with Example 1, the only difference is that it is prepared using the following raw materials: ginseng 2kg, astragalus 10kg, coconut flesh 1kg, cistanche 10kg, yam 6kg, wolfberry 6kg, Poria cocos 6kg, cinnamon 1kg, licorice 3kg.
實施例8Example 8
本實施例提供了一種補腎壯陽的片劑,其以實施例1提供的組合物為有效成分,還進一步加入如下輔料:羥甲基纖維素鈉0.25kg,乾澱粉0.75kg,硬脂酸鎂0.05kg,糖精鈉0.25kg,微晶纖維素0.5kg。This example provides a tablet for invigorating the kidney and aphrodisiac, which uses the composition provided in Example 1 as an active ingredient, and further adds the following excipients: sodium hydroxymethyl cellulose 0.25 kg, dry starch 0.75 kg, and magnesium stearate 0.05 kg, saccharin sodium 0.25kg, microcrystalline cellulose 0.5kg.
所述片劑採用如下方法製備而成:將所述組合物與乾澱粉、糖精鈉以及微晶纖維素混合均勻,再加入羥甲基纖維素鈉,混合均勻,濕粒乾燥後,整粒,再加入硬脂酸鎂,混合均勻,壓片製成片劑。The tablet is prepared by the following method: mixing the composition with dry starch, sodium saccharin and microcrystalline cellulose, and then adding sodium hydroxymethylcellulose, mixing evenly, after the wet granules are dried, the whole granules, Add magnesium stearate, mix well, and press to make tablets.
實施例9Example 9
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例2提供的組合物為有效成分。This example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 2 is used as an active ingredient.
實施例10Example 10
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例3提供的組合物為有效成分。This example provides a tablet for kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 3 is used as an active ingredient.
實施例11Example 11
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例4提供的組合物為有效成分。This example provides a tablet for kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 4 is used as an active ingredient.
實施例12Example 12
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例5提供的組合物為有效成分。This example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 5 is used as an active ingredient.
實施例13Example 13
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例6提供的組合物為有效成分。This example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 6 is used as an active ingredient.
實施例14Example 14
本實施例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,以實施例7提供的組合物為有效成分。This example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that the composition provided in Example 7 is used as an active ingredient.
對比例1Comparative Example 1
本對比例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,作為有效成分的組合物中不使用椰子瓤。This comparative example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that no coconut flakes are used in the composition as an active ingredient.
對比例2Comparative Example 2
本對比例提供了一種補腎壯陽的片劑,與實施例8相比,區別僅在於,作為有效成分的組合物中,用薏苡仁代替所述椰子瓤。The present comparative example provides a tablet for invigorating the kidney and aphrodisiac. Compared with Example 8, the only difference is that in the composition as an active ingredient, coix seed is used instead of the coconut flesh.
實驗例1Experimental Example 1
本實驗例檢測了各實施例和對比例提供的片劑對便秘的治療效果。In this experimental example, the therapeutic effect of the tablets provided in the examples and comparative examples on constipation was tested.
選取確診為便秘的患者每組40人。供試者符合如下標準,①便秘病程大於6個月,最近3個月有症狀發作;②年齡大於16歲,小於80歲者;③患者簽署知情同意書,自願參加本研究。Select 40 patients in each group who were diagnosed with constipation. The test subjects met the following criteria: ① The course of constipation was greater than 6 months, with symptom onset in the last 3 months; ② Those older than 16 years old and less than 80 years old; ③ The patients signed an informed consent and voluntarily participated in the study.
每位患者每天服藥一次,每次0.033g/kg。Each patient takes the medicine once a day, 0.033g/kg each time.
便秘臨床評分:①自主排便:有(0分),借助藥物、手助或灌腸排便(3分);②便意感:有(0分), 無(1分);③自行排便頻率:1~2日排便一次(0分),3~4日排便一次(1分),5~6日排便一次(2分),6日以上排便一次(3分),不能自行排便(4分);④排便費力程度:自然排便,無排便費力(0分),須用力排便(1分),努掙方能排便(2分);⑤每次排便時間:1~10 min(0分),11~20 min(1分),21~30 min(2分),30 min以上(3分);⑥便質:硬塊散在(3分),硬塊成條(2分),呈條有裂紋(1分),成條光軟(0分);⑦腹脹、腹痛、排便不盡感、肛門墜脹感、肛門梗阻感、排氣不暢感6個症狀均以無(0分),輕微(1分),明顯(2分),難忍(3分)4級來評分。Constipation clinical score: ① voluntary defecation: yes (0 points), defecation with the aid of drugs, hand-assisted or enema (3 points); ② sense of constipation: yes (0 points), no (1 point); ③ self-defecation frequency: 1~ One bowel movement on the 2nd (0 points), one bowel movement on the 3rd to 4th days (1 point), one bowel movement on the 5th to 6th days (2 points), and one bowel movement on the 6th or more days (3 points), you cannot defecate yourself (4 points); ④ Defecation effort level: natural defecation, no defecation effort (0 points), defecation effort (1 point), hard work to defecation (2 points); ⑤ time for each bowel movement: 1~10 min (0 points), 11~ 20 min (1 point), 21~30 min (2 points), more than 30 min (3 points); ⑥ Feces: hard blocks scattered (3 points), hard blocks into strips (2 points), showing cracks (1 point) ), into a strip of light and soft (0 points); ⑦ abdominal distension, abdominal pain, endless bowel sensation, anal bloating, anal obstruction, poor exhaust feeling 6 symptoms are none (0 points), mild (1 point) ), obviously (2 points), unbearable (3 points) 4 grades.
療效評定標準《中藥新藥臨床研究指導原則》,並結合臨床,自擬以下主症療效評價標準:①臨床痊癒:主症消失,排便正常,便秘臨床症狀積分為0;②顯效:臨床症狀明顯改善,臨床症狀積分較治療前降低≥2/3;③有效:臨床症狀好轉,但臨床症狀積分降低1/2~2/3;④好轉:臨床症狀出現好轉,但臨床症狀積分較治療前降低≤1/2;⑤無效:臨床症狀無改善或加重,臨床症狀積分無降低或反而升高。Efficacy evaluation standard "Guiding Principles of Clinical Research on New Drugs of Traditional Chinese Medicine", combined with the clinical, self-made the following evaluation criteria for the efficacy of the main symptoms: ① clinical recovery: the main symptoms disappear, normal bowel movements, and the clinical symptom score of constipation is 0; ② marked effect: the clinical symptoms have improved significantly , Clinical symptom score decreased by ≥2/3 compared with before treatment; ③ Effective: Clinical symptoms improved, but clinical symptom score decreased by 1/2~2/3; ④ Improved: Clinical symptoms improved, but clinical symptom score decreased than before treatment ≤ 1/2; ⑤ Ineffective: No improvement or aggravation of clinical symptoms, and no decrease or increase of clinical symptom scores.
治療結果如表1所示。The treatment results are shown in Table 1.
表1:便秘治療效果
實驗例2Experimental Example 2
本實驗例驗證了實施例9、13、14提供的片劑的補腎壯陽效果。This experimental example verified the effect of the tablets provided in Examples 9, 13, and 14 on kidney and aphrodisiac.
選取昆明種雄鼠80隻,體重18-22g,每組10隻,隨機分為6組:正常對照組、模型對照組、陽性對照組、對比例1、對比例2、實施例9、實施例13、實施例14。Eighty Kunming male rats weighing 18-22g, each group of 10 rats, were randomly divided into 6 groups: normal control group, model control group, positive control group, comparative example 1, comparative example 2, example 9, example 13 、实施例14。 Example 14.
除正常對照組外,各組均每天腹腔注射氫化可的松25mg▪kg-1 ,製備腎陽虛模型。陽性對照組皮下注射丙酸睾丸酮溶液2mg▪kg-1 ,其餘按劑量給藥。連續給藥七天,每天給藥33mg▪kg-1 ,末次給藥1h後用生理藥理電子刺激儀的刺激電極至於小鼠陰莖部位,電流強度為0.2mA,電壓為150mV,記錄自刺激開始至陰莖勃起時間(勃起潛伏期),結果見表2。Except for the normal control group, each group was intraperitoneally injected with hydrocortisone 25mg·kg -1 to prepare a kidney-yang deficiency model. The positive control group was injected subcutaneously with a testosterone propionate solution 2 mg·kg -1 , and the rest was dosed. Continuous administration for 7 days, daily administration of 33 mg kg -1 , 1 hour after the last administration, the stimulation electrode of the physiological pharmacological electronic stimulator was applied to the penis of the mouse, the current intensity was 0.2 mA, and the voltage was 150 mV, recording from the start of stimulation to the penis The erection time (erection incubation period), the results are shown in Table 2.
表2:組合物對小鼠陰莖勃起潛伏期的影響
末次給藥24h後處死小鼠,摘除前列腺+精囊腺、睾丸、包皮腺,分離周圍脂肪等結締組織。立即稱量前列腺+精囊腺、睾丸和包皮腺質量,結果見表3。The mice were sacrificed 24 hours after the last administration, the prostate + seminal vesicles, testes, and foreskin were removed, and the connective tissues such as surrounding fat were separated. Weigh the prostate + seminal vesicles, testes and prepuce glands immediately. The results are shown in Table 3.
表3:組合物對小鼠性器官的影響(mg/kg.bw)
實驗例3Experimental Example 3
本實驗例驗證了實施例14提供的片劑的增強免疫力效果。This experimental example verifies the immunity-enhancing effect of the tablet provided in Example 14.
選取昆明種小鼠180隻,體重18-22g,隨機分為3大組,每大組分為4小組,每小組10隻:正常對照組、對比例1(33mg▪kg-1 )、對比例2(33mg▪kg-1 )、實施例14提供的片劑的低劑量組(具體劑量為33mg▪kg-1 )、實施例14提供的片劑的中劑量組(具體劑量為66mg▪kg-1 )、實施例14提供的片劑的高劑量組(具體劑量為165mg▪kg-1 ),給小鼠灌胃,對照組灌胃予以等體積蒸餾水,每天一次,連續給藥30天後測定如下指標。ConA誘導小鼠脾淋巴細胞轉化結果見表4,小鼠遲髮型態反應結果見表5,NK細胞活性的測定結果見表6。180 Kunming mice were selected, weighing 18-22g, and randomly divided into 3 groups, with each group consisting of 4 groups and 10 mice in each group: normal control group, comparative example 1 (33mg ▪ kg -1 ), comparative example 2 (33mg▪kg -1), Example 14 provides a low-dose tablet (specifically dose 33mg▪kg -1), medium dose group (provided that the specific dose tablet of Example 14 embodiment 66mg▪kg - 1 ). In the high-dose group of tablets provided in Example 14 (the specific dose is 165 mg·kg -1 ), mice are gavaged, and the control group is gavaged with an equal volume of distilled water, once a day, measured after 30 days of continuous administration The following indicators. The results of ConA-induced splenic lymphocyte transformation in mice are shown in Table 4, the results of delayed-type hyperactivity in mice are shown in Table 5, and the measurement results of NK cell activity are shown in Table 6.
表4:ConA誘導小鼠脾淋巴細胞轉化實驗
表5:小鼠遲髮型態反應
表6:NK細胞活性的測定(x(一)±s)
從表4、表5、表6可看出與空白組對比,低、中、高劑量3個組均可顯著提高正常小鼠淋巴細胞增殖能力、足蹠腫脹度及NK細胞活性。表明本組合物具有提高機體免疫力,增強機體抗病能力的作用。It can be seen from Table 4, Table 5 and Table 6 that compared with the blank group, the three groups of low, medium and high doses can significantly improve the lymphocyte proliferation ability, foot and plantar swelling and NK cell activity of normal mice. This shows that the composition has the effects of improving the immunity of the body and the disease resistance of the body.
實驗例5Experimental Example 5
本實驗例驗證了實施例14提供的片劑的延緩衰老效果。This experimental example verified the anti-aging effect of the tablet provided in Example 14.
選取昆明種小鼠70隻,體重18-22g,隨機分為5組,每組10隻:正常對照組、對比例例1(33mg▪kg-1 )、對比例2(33mg▪kg-1 )、低劑量組(具體劑量為33mg▪kg-1 )、中劑量組(具體劑量為66mg▪kg-1 )、高劑量組(具體劑量為165mg▪kg-1 )。除空白對照組外其餘各組每天頸背下注射0.5mL5%D-半乳糖溶液,對照組予以等體積生理鹽水,每天一次,連續給予小鼠受試物30天後,測定血清、肝臟、腦組織丙二醛(MDA)含量及超氧化物歧化酶(Superoxide dismutase,SOD)活性結果見表7以及表8。70 Kunming mice, weighing 18-22g, were randomly divided into 5 groups of 10 mice each: normal control group, comparative example 1 (33mg ▪ kg -1 ), comparative example 2 (33mg ▪ kg -1 ) , Low-dose group (specific dose is 33mg kg -1 ), medium-dose group (specific dose 66mg ▪ kg -1 ), high-dose group (specific dose 165mg ▪ kg -1 ). Except for the blank control group, the other groups were injected with 0.5 mL of 5% D-galactose solution under the neck every day. The control group was given an equal volume of normal saline once a day. After 30 days of continuous administration of the test substance to mice, serum, liver, and brain were measured. The results of tissue malondialdehyde (MDA) content and superoxide dismutase (SOD) activity are shown in Table 7 and Table 8.
表7:對小鼠MDA含量的影響
表8:對小鼠SOD活性的影響
由以上結果可知,本發明組合物可以降低血清、肝臟、腦組織中MDA含量,可以提高血清、肝臟、腦組織中SOD活性,達到延緩衰老的作用。From the above results, it can be seen that the composition of the present invention can reduce the content of MDA in serum, liver, and brain tissue, can increase the SOD activity in serum, liver, and brain tissue, and achieve the effect of delaying aging.
雖然,上文中已經用一般性說明、具體實施方式及試驗,對本發明作了詳盡的描述,但在本發明基礎上,可以對之作一些修改或改進,這對本領域中具有通常知識者而言是顯而易見的。因此,在不偏離本發明精神的基礎上所做的這些修改或改進,均屬本發明要求保護的範圍。Although the present invention has been described in detail with general descriptions, specific embodiments and experiments, but on the basis of the present invention, some modifications or improvements can be made to it, which is for those with ordinary knowledge in the field It is obvious. Therefore, these modifications or improvements made on the basis of not deviating from the spirit of the present invention are within the scope of the claimed invention.
無。no.
無。no.
無。no.
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810929680.3 | 2018-08-15 | ||
CN201810929680.3A CN108815332A (en) | 2018-08-15 | 2018-08-15 | A kind of composition of tonifying kidney and strengthening yang and the preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI693939B TWI693939B (en) | 2020-05-21 |
TW202019455A true TW202019455A (en) | 2020-06-01 |
Family
ID=64150695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108102289A TWI693939B (en) | 2018-08-15 | 2019-01-21 | Composition for invigorating kidney and strengthening yang, preparation method and application thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN108815332A (en) |
HK (1) | HK1257802A1 (en) |
TW (1) | TWI693939B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110279809A (en) * | 2019-07-11 | 2019-09-27 | 北京中京丰创科技有限公司 | A kind of composition of enriching yin and nourishing kidney and the preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1103780A (en) * | 1993-12-17 | 1995-06-21 | 龚建平 | Skin-care cosmetics containing ethanolic extract of coconut pulp |
KR20020085401A (en) * | 2001-05-08 | 2002-11-16 | 주식회사 허브넥스 | Composition for the prophylaxis or treatment of male reproductivity depression, or for the stimulation of haematogenesis |
CN102908470B (en) * | 2012-11-13 | 2014-09-24 | 李健民 | Chinese materia medica preparation for tonifying Yang and preparation method thereof |
CN106421432A (en) * | 2016-12-11 | 2017-02-22 | 郑州众易软件开发有限公司 | Traditional Chinese medicine for treating aged body deficiency syndrome and delaying senescence |
-
2018
- 2018-08-15 CN CN201810929680.3A patent/CN108815332A/en active Pending
- 2018-12-04 HK HK18115479.8A patent/HK1257802A1/en unknown
-
2019
- 2019-01-21 TW TW108102289A patent/TWI693939B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TWI693939B (en) | 2020-05-21 |
HK1257802A1 (en) | 2019-11-01 |
CN108815332A (en) | 2018-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
CN104645186A (en) | Traditional Chinese medicine composition for strengthening physique and improving immunity and preparation method thereof | |
TWI693939B (en) | Composition for invigorating kidney and strengthening yang, preparation method and application thereof | |
CN103638475A (en) | Traditional Chinese medicinal spray for treating lump in breast and preparation method thereof | |
TWI721367B (en) | Composition for regulating endocrine, improving immunity, delaying aging and preventing or treating constipation, its application and preparation method thereof | |
CN104432386B (en) | Sangjisheng oral liquid for preventing soreness of waist and knees and weakness of muscles and bones and preparation method thereof | |
CN103301341A (en) | Traditional Chinese medicine composition of treating ischemic cerebral apoplexy | |
CN103157062A (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
CN114224998A (en) | A traditional Chinese medicine composition, preparation and application for treating functional dyspepsia of spleen and kidney yang deficiency type | |
CN108815501B (en) | Traditional Chinese medicine composition for treating infantile cough and asthma and preparation method and application thereof | |
CN100374136C (en) | A deer antler capsule | |
CN112023010A (en) | Traditional Chinese medicine composition for slimming, preparation method thereof, oral medicine and application | |
CN110279809A (en) | A kind of composition of enriching yin and nourishing kidney and the preparation method and application thereof | |
CN104998074A (en) | Traditional Chinese medicine for treating gastropathy and preparation method thereof | |
CN103431277B (en) | Mixed-grain total-nutrition formulation food for traumatic or surgical patients | |
CN116549595B (en) | Pharmaceutical composition for treating functional dyspepsia of children, preparation and application thereof | |
CN106729584A (en) | It is a kind of to treat Chinese medicine composition of baby anorexia and preparation method thereof | |
CN106039030A (en) | Granules capable of clearing bowels, expelling toxins and beautifying face | |
CN104623563A (en) | Traditional-Chinese-medicine preparation for postoperative rehabilitation of sigmoid colon cancer | |
CN104857371A (en) | Medicine for treating colon cancer and preparation method thereof | |
CN115624595A (en) | Health-preserving kidney tea | |
CN118903359A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver fibrosis | |
CN104510874A (en) | Traditional Chinese medicine granules for treatment of postpartum stool stagnation and preparation method thereof | |
CN104324196A (en) | Traditional Chinese medicine composition used for treating leucoderma and decoction, pill and powder thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |